


फा.सं. / F. No. 50014/03/2020-CDN  
भारत सरकार / Government of India  
रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers  
औषध विभाग / Department of Pharmaceuticals

शास्त्री भवन, नई दिल्ली  
Shastri Bhawan, New Delhi  
Dated: 15<sup>th</sup> April, 2021

**Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of March, 2021-reg.**

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of March, 2021 for information.

  
(Meera Mamgaain)  
Under Secretary to the Govt. of India  
Tel: 011 23385473  
Email: [mamgaain.meera@nic.in](mailto:mamgaain.meera@nic.in)

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. PSO to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.



**Ministry of Chemicals & Fertilizers**  
**Department of Pharmaceuticals**  
**Monthly Summary for the Month of March, 2021**

Important events for the Month of **March, 2021** are as follows:

**(i) IMPORTANT POLICY DECISIONS:**

Cabinet has approved proposal for amendment of NIPER, Act in its meeting held on 10.02.2021. Subsequently, amendment Bill introduced in Lok Sabha on 15.03.2021. Due to adjournment of Parliament before scheduled time, it could not be listed for discussion in Budget Session.

**(ii) MAJOR ACHIEVEMENTS:**

- (a) The NPPA has fixed ceiling prices of 01 medicine during March, 2021 bringing the cumulative figure to 882 till March, 2021.
- (b) Retail prices of 76 new medicines have been fixed during March, 2021 bringing cumulative figure to 1589 till March, 2021.
- (c) Heparin Injection is considered as an essential drug for COVID management Accordingly, the revised price of Heparin Injection 1000IU/ml and Heparin Injection 5000IU/ml was extended up to 30.09.2021 or until further order, whichever is earlier, to ensure continuous availability especially during the pandemic situation of COVID-19.
- (d) The price ceiling of Medical Oxygen was extended up to 30.09.2021 or until further order, whichever is earlier in view of continuing extraordinary circumstances due to the COVID pandemic.
- (e) The ceiling prices of 882 scheduled formulations have been revised based on WPI applicable from 01.04.2021
- (f) Price Monitoring and Resource Unit (PMRU) have been set up in 18 States against the target of 18 PMRUs consolidated by 2021-21, viz., Kerala, Gujrat, Odisha, Rajasthan, Punjab, Haryana, Tripura, Nagaland, Uttar Pradesh, Andhra Pradesh, Mizoram, Jammu & Kashmir, Karnataka, Telangana, Maharashtra, Goa, Madhya Pradesh and Chhattisgarh.
- (g) Total overcharged amount received during March, 2021 is Rs. 40.86 Lakhs.
- (h) 79 Jan Aushadhi Kendras under Pradhan Mantri Bhartiya Janaushadhi Pariyojna (PMBJP) were opened during March, 2021 across the country.
- (i) Out of 622 Research Papers published during the current financial year, 74 papers has been published in March, 2021.
- (j) Out of 37 Patents filed during the current financial year, 8 patents has been filed during the March, 2021.



(iii) **MAJOR EVENTS:**

Under Production Linked Incentive (PLI) Schemes status of applications is as follows:

Sl. No.	Scheme Name	Number of applications approved in the month of March, 2021	Total no. of applications approved till March, 2021	Total number of applications received till March, 2021
1.	Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India	16*	47	215
2.	Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices	0	14	28

\* Empowered Committee approved 16 applications. The file is under submission for approval of Hon'ble Minister (C&F)

(iv) The details of grievances during the **March, 2021** are as under:

No. of grievances at the start of the month	No. of grievances received during the month	No. of grievances disposed	No. of grievances pending at end of the month
89	141	162	68

(v) FDI proposals: -

(a) Pending at beginning of the month	:-	8
(b) Received during the month	:-	5
(c) Disposed of during the month	:-	1
(d) Pending at end of the month	:-	12

\*\*\*\*\*